...
首页> 外文期刊>The Journal of Immunology: Official Journal of the American Association of Immunologists >Defective expression of the monocyte chemotactic protein-1 receptor CCR2 in macrophages associated with human ovarian carcinoma.
【24h】

Defective expression of the monocyte chemotactic protein-1 receptor CCR2 in macrophages associated with human ovarian carcinoma.

机译:单核细胞趋化蛋白-1受体CCR2在与人类卵巢癌相关的巨噬细胞中的缺陷表达。

获取原文
获取原文并翻译 | 示例
           

摘要

Monocyte chemotactic protein-1 (MCP-1, CCL2) is an important determinant of macrophage infiltration in tumors, ovarian carcinoma in particular. MCP-1 binds the chemokine receptor CCR2. Recent results indicate that proinflammatory and anti-inflammatory signals regulate chemokine receptor expression in monocytes. The present study was designed to investigate the expression of CCR2 in tumor-associated macrophages (TAM) from ovarian cancer patients. TAM isolated from ascitic or solid ovarian carcinoma displayed defective CCR2 mRNA (Northern blot and PCR) and surface expression and did not migrate in response to MCP-1. The defect was selective for CCR2 in that CCR1 and CCR5 were expressed normally in TAM. CCR2 gene expression and chemotactic response to MCP-1 were decreased to a lesser extent in blood monocytes from cancer patients. CCR2 mRNA levels and the chemotactic response to MCP-1 were drastically reduced in fresh monocytes cultured in the presence of tumor ascites from cancer patients. Ab against TNF-alpha restored the CCR2 mRNA level in monocytes cultured in the presence of ascitic fluid. The finding of defective CCR2 expression in TAM, largely dependent on local TNF production, is consistent with previous in vitro data on down-regulation of chemokine receptors by proinflammatory molecules. Receptor inhibition may serve as a mechanism to arrest and retain recruited macrophages and to prevent chemokine scavenging by mononuclear phagocytes at sites of inflammation and tumor growth. In the presence of advanced tumors or chronic inflammation, systemic down-regulation of receptor expression by proinflammatory molecules leaking in the systemic circulation may account for defective chemotaxis and a defective capacity to mount inflammatory responses associated with advanced neoplasia.
机译:单核细胞趋化蛋白-1(MCP-1,CCL2)是肿瘤尤其是卵巢癌中巨噬细胞浸润的重要决定因素。 MCP-1结合趋化因子受体CCR2。最近的结果表明促炎和消炎信号调节单核细胞中趋化因子受体的表达。本研究旨在研究CCR2在卵巢癌患者肿瘤相关巨噬细胞(TAM)中的表达。从腹水或固体卵巢癌中分离出的TAM显示出缺陷的CCR2 mRNA(Northern印迹和PCR)和表面表达,并且不响应MCP-1而迁移。该缺陷对CCR2具有选择性,因为CCR1和CCR5在TAM中正常表达。在癌症患者的血液单核细胞中,CCR2基因表达和对MCP-1的趋化反应降低程度较小。在患有癌症患者的肿瘤腹水的情况下培养的新鲜单核细胞中,CCR2 mRNA水平和对MCP-1的趋化性反应显着降低。抗TNF-α的抗体可恢复腹水存在下培养的单核细胞中CCR2 mRNA的水平。在TAM中发现CCR2表达缺陷主要取决于局部TNF的产生,这与先前关于促炎分子下调趋化因子受体的体外数据一致。受体抑制作用可作为一种机制,以阻止和保留募集的巨噬细胞并防止炎症和肿瘤生长部位的单核吞噬细胞清除趋化因子。在存在晚期肿瘤或慢性炎症的情况下,通过在体循环中泄漏的促炎分子的全身性下调受体表达可能解释了趋化性缺陷和与晚期肿瘤形成相关的引起炎症反应的能力不足。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号